Abstract:Background: Proteins overexpressed on the surface of tumor cells can be selectively targeted. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are among the most often targeted proteins. The level and stability of expression in both primary tumors and corresponding metastases is crucial in the assessment of a receptor as target for imaging in nuclear medicine and for various forms of therapy. So far, the expression of EGFR and HER2 has only been determined in primary cervical cancers, and we have not found published data regarding the receptor status in corresponding metastatic lesions. The goal of this study was to evaluate whether any of these receptors are suitable as target for clinical diagnosis and therapy.Methods: Expression of EGFR and HER2 was investigated immunohistochemically in both lymph node metastases and corresponding primary cervical cancers (n = 53). HER2 and EGFR expression was scored using HercepTest criteria (0, 1+, 2+ or 3+).Results: EGFR overexpression (2+ or 3+) was found in 64% (35/53) of the primary cervical tumors and 60% (32/53) of the corresponding lymph node metastases. There was a good concordance between the primary tumors and the paired metastases regarding EGFR expression. Only four patients who had 2+ or 3+ in the primary tumors changed to 0 or 1+ in lymph node metastases, and another two cases changed the other way around. None of the primary tumors or the lymph node metastases expressed HER2 protein.Conclusion: The EGFR expression seems to be common and stable during cervical cancer metastasis, which is encouraging for testing of EGFR targeted radiotherapy. HER2 appears to be of poor interest as a potential target in the treatment of cervical cancer.

Structural Basis for EGFR Transmembrane Signaling and Its Implications in Therapeutic Development

Development of Egfr Family Small Molecule Inhibitors for Anticancer Intervention: an Overview of Approved Drugs and Clinical Candidates

Epidermal growth factor receptor (EGFR) and its signal transduction

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

Insight into the Medicinal Chemistry of Egfr and Her-2 Inhibitors

Epidermal Growth Factor Receptor Family Tyrosine Kinase and Cancer Therapy

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

Structural Analysis of the EGFR TK Domain and Potential Implications for EGFR Targeted Therapy

[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].

[Regulation on EGFR Function Via Its Interacting Proteins and Its Potential Application].

Advances in Anti-Tumor Therapy Targeting the EGFR Family of Receptor Tyrosine Kinases

Can EGFR be a therapeutic target in breast cancer?

Targeting the EGFR signaling pathway in cancer therapy

[Tumor Biotherapy Based on Epidermal Growth Factor Receptor As a Target].

Structure and dynamics of the EGFR/HER2 heterodimer

Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics

Progress of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors in the Cancer Therapy

Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents